@ARTICLE{
author={Verschraegen Claire,Andric Zoran G,...,(broj koautora 20)},
year={2022},
title={1-year follow-up of a phase III study to compare efficacy and safety of a bevacizumab biosimilar, CT-P16, and reference bevacizumab as first-line treatment for metastatic or recurrent non-squamous non-small cell lung cancer},
journal={ANNALS OF ONCOLOGY},
volume={33},
number={7},
pages={S1024-S1025},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Verschraegen Claire,Andric Zoran G,Moiseenko Fedor,Makharadze Tamta,Shevnya Sergii,Oleksiienko Alona,Ruiz Eduardo Yanez,Kim SungHyun,Ahn KeumYoung,Park TaeHong,Park Sijin,Ju Hana,Ohe Yuichiro},
year={2022},
title={Candidate Bevacizumab Biosimilar CT-P16 versus European Union Reference Bevacizumab in Patients with Metastatic or Recurrent Non-Small Cell Lung Cancer: A Randomized Controlled Trial},
journal={BIODRUGS},
volume={36},
number={6},
pages={749-760},
document_type={Article},
}